CLAIMS

1. Use of an antagonist of a Programmed Death 1 protein (PD-1) and a vascular endothelial growth factor receptor (VEGFR) inhibitor for the manufacture of a medicament for combination therapy treatment of a cancer in an individual, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22, respectively, and further wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl- vinyl)- l*H*-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, wherein the individual is a human.

3. The use according to claim 1 or 2, wherein the cancer is a solid tumor.

4. The use according to claim 1 or 2, wherein the cancer is renal cell carcinoma.

5. The use according to any one of claims 1 to 4, wherein the PD-1 antagonist is pembrolizumab and the VEGFR inhibitor is axitinib.

6. The use of any one of claims 1-3, wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma, lung squamous cell carcinoma, malignant melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small-cell lung cancer (SCLC), triple negative breast cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin’s lymphoma (HL), mantle cell lymphoma (MCL), multiple myeloma (MM), myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), or small lymphocytic lymphoma (SLL).